News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
489,642 Results
Type
Article (8026)
Company Profile (147)
Press Release (481469)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166743)
Career Advice (304)
Deals (25741)
Drug Delivery (7)
Drug Development (52881)
Employer Resources (14)
FDA (9763)
Job Trends (8573)
News (238203)
Policy (17903)
Tag
2025 Best Places to Work (5)
2026 Best Places to Work (12)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Digital (1)
2027 Pharm Country Standard (1)
Academia (502)
Accelerated approval (31)
ADA (18)
Adcomms (1)
Allergies (103)
Alliances (33156)
ALS (122)
Alzheimer's disease (1017)
Antibody-drug conjugate (ADC) (336)
Approvals (10497)
Artificial intelligence (382)
ASCO (160)
Autoimmune disease (259)
Automation (34)
Bankruptcy (264)
Belgium (4)
Best Places to Work (6958)
BIO (36)
Biologics (61)
BIOSECURE Act (1)
Biosimilars (126)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (30)
Bladder cancer (149)
Brain cancer (36)
Breast cancer (553)
Cancer (4132)
Cardiovascular disease (247)
Career advice (245)
Career pathing (1)
CAR-T (195)
CDC (2)
CDMO (36)
Celiac Disease (3)
Cell therapy (534)
Cervical cancer (37)
Clinical research (48628)
Collaboration (1381)
Commercialization (34)
Compensation (1666)
Complete response letters (36)
COVID-19 (778)
CRISPR (75)
C-suite (871)
Cystic fibrosis (89)
Data (6713)
Denatured (4)
Depression (109)
Dermatology (106)
Diabetes (389)
Diagnostics (4285)
Digital health (43)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (176)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (176)
Earnings (74509)
Editorial (1)
Employer branding (2)
Employer resources (14)
ESMO (240)
Events (89242)
Executive appointments (744)
Eye disease (7)
FDA (12744)
Fibrodysplasia Ossificans Progressiva (12)
Fragile X (1)
Friedreich's ataxia (21)
Frontotemporal dementia (25)
Funding (1010)
Gene editing (140)
Generative AI (15)
Gene therapy (359)
GLP-1 (319)
Government (956)
Grass and pollen (2)
Guidances (288)
Healthcare (9448)
Hematology (115)
HIV (60)
Huntington's disease (30)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (82)
Immunology and inflammation (114)
Immuno-oncology (75)
Indications (189)
Infectious disease (988)
Inflammatory bowel disease (145)
Inflation Reduction Act (4)
Influenza (90)
Intellectual property (275)
Interviews (41)
IPO (12401)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (19)
Kidney disease (91)
Layoffs (59)
Legal (5195)
Licensing (65)
Liver cancer (47)
Longevity (28)
Lung cancer (588)
Lung diease (11)
Lymphoma (282)
Machine learning (30)
Management (3)
Manufacturing (630)
Marketing (25)
MASH (131)
Medical affairs (2)
Medical device (8728)
Medtech (8930)
Mergers & acquisitions (14490)
Metabolic disorders (792)
mRNA (82)
Multiple sclerosis (118)
Multispecific (3)
NASH (4)
Netherlands (4)
Neurodegenerative disease (250)
Neuropsychiatric disorders (41)
Neuroscience (1991)
Neurotech (2)
NextGen: Class of 2026 (3151)
Non-profit (845)
Obesity (246)
Opinion (10)
Ovarian cancer (184)
Pain (195)
Pancreatic cancer (237)
Parkinson's disease (220)
Partnered (12)
Patents (532)
Patient advocacy (3)
Patient recruitment (550)
Patient selection (55)
Peanut (34)
People (41575)
Peptides (24)
Pharmaceutical (30)
Pharmacy benefit managers (11)
Phase 1 (15703)
Phase 2 (21750)
Phase 3 (14672)
Pipeline (9037)
Policy (20)
Postmarket research (1570)
Preclinical (6619)
Press Release (34)
Prostate cancer (211)
Psychedelics (12)
Radiopharmaceuticals (205)
Rare diseases (640)
Real estate (3025)
Recruiting (6)
Regenerative medicine (18)
Regulatory (15261)
Reports (27)
Research institute (596)
Resumes & cover letters (45)
Rett syndrome (47)
RNA editing (9)
RSV (52)
Schizophrenia (111)
Series A (179)
Series B (128)
Service/supplier (5)
Sickle cell disease (70)
Spinal muscular atrophy (93)
Sponsored (5)
Startups (2021)
Stem cells (3)
Stomach cancer (3)
Substance use disorders (17)
Supply chain (56)
Switzerland (2)
Tariffs (2)
Vaccines (362)
Venture capital (18)
Weight loss (79)
Wet AMD (3)
Women's health (102)
Date
Last 7 days (624)
Last 30 days (2235)
Last 365 days (19113)
2026 (17266)
2025 (19252)
2024 (22988)
2023 (26538)
2022 (34591)
2021 (37172)
2020 (33468)
2019 (23256)
2018 (17468)
2017 (18765)
2016 (17918)
2015 (24264)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (233)
Alabama (81)
Alaska (2)
Arizona (331)
Arkansas (12)
Asia (18097)
Australia (2129)
California (13384)
Canada (3451)
China (594)
Colorado (549)
Connecticut (471)
Delaware (236)
Europe (24858)
Florida (1992)
Georgia (420)
Hawaii (3)
Idaho (46)
Illinois (802)
India (66)
Indiana (339)
Iowa (19)
Japan (466)
Kansas (105)
Kentucky (34)
Louisiana (30)
Maine (27)
Maryland (1317)
Massachusetts (8759)
Michigan (325)
Minnesota (623)
Mississippi (5)
Missouri (86)
Montana (20)
Nebraska (11)
Nevada (140)
New Hampshire (61)
New Jersey (2944)
New Mexico (12)
New York (3121)
North Carolina (1416)
North Dakota (4)
Northern California (6802)
Ohio (311)
Oklahoma (15)
Oregon (17)
Pennsylvania (2493)
Puerto Rico (24)
Rhode Island (32)
South America (407)
South Carolina (81)
South Dakota (1)
Southern California (5594)
Tennessee (131)
Texas (2209)
United States (43276)
Utah (405)
Vermont (1)
Virginia (169)
Washington D.C. (39)
Washington State (1019)
West Virginia (1)
Wisconsin (84)
Wyoming (1)
489,642 Results for "kempharm inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
KemPharm Issues Letter to Shareholders - January 24, 2023
KemPharm, Inc. today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Letter to Shareholders.
January 24, 2023
·
12 min read
KemPharm Announces Corporate Name Change to Zevra Therapeutics
KemPharm, Inc. announced today that it changed its name to Zevra Therapeutics, Inc. (“Zevra”).
February 22, 2023
·
7 min read
Business
KemPharm Enhances Senior Management Team
KemPharm, Inc. announced that it has named Daniel Gallo, Ph.D., as Senior Vice President of Medical Affairs and Advocacy, and Abbi Maher, J.D., as Vice President of Legal Affairs.
January 31, 2023
·
4 min read
Deals
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (“KemPharm”).
May 17, 2022
·
4 min read
Business
KemPharm Announces Appointment of Christopher Posner as New Independent Director
KemPharm, Inc. today announced the appointment of Christopher Posner to serve on the Company’s Board of Directors.
November 29, 2022
·
6 min read
FDA
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
KemPharm, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted the Orphan Drug Designation to serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH), for the treatment of idiopathic hypersomnia (IH), a rare neurological sleep disorder.
November 18, 2022
·
6 min read
Business
KemPharm Reports Third Quarter 2022 Results
KemPharm, Inc., a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, reported its financial results for the quarter ended September 30, 2022.
November 9, 2022
·
13 min read
Business
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
KemPharm, Inc. reported its financial results for the second quarter ended June 30, 2022.
August 11, 2022
·
13 min read
KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference
KemPharm, Inc. today announced that Richard W. Pascoe, Executive Chairman of KemPharm, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022.
August 2, 2022
·
1 min read
KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation at the H.C. Wainwright 24th Annual Global Investment Conference being held from September 12-14, 2022, in New York, New York.
September 1, 2022
·
2 min read
1 of 48,965
Next
